Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Pharmasset Enters into a Clinical Collaboration Agreement with Tibotec Pharmaceuticals for a Combination Study in Patients Chronically Infected with Hepatitis C

By Pharmaceutical Processing | July 6, 2011

 

Pharmasset, Inc., announced today that it has entered into a
clinical collaboration agreement with Tibotec Pharmaceuticals to evaluate in a Phase
2 study the safety and efficacy of PSI-7977, Pharmasset’s investigational
nucleotide polymerase inhibitor, in combination with TMC435, Tibotec Pharmaceuticals’
investigational protease inhibitor, for the treatment of chronic hepatitis C
virus (HCV).

This phase 2 proof of concept study will evaluate the
potential to achieve sustained virologic response 12 weeks post treatment with
an all oral, once-daily, interferon-free treatment regimen in patients infected
with genotype 1 HCV. Specifically, the study will assess the safety,
pharmacokinetics and pharmacodynamics of 12 and 24 weeks of PSI-7977 in
combination with TMC435, with and without ribavirin, in patients chronically
infected with HCV genotype 1 who had a prior null response to peginterferon
alfa and ribavirin treatment. The study is planned to start in the second half
of 2011.

“We are excited to be working with Tibotec to simplify
and improve HCV treatment,” stated Bill Symonds, PharmD, Pharmasset’s
Senior Vice President of Clinical Pharmacology and Translational Medicine.

“PSI-7977 is now being studied in interferon-free
combinations with each of the three leading classes of direct-acting
antivirals: Tibotec’s protease inhibitor, Bristol-Myers Squibb’s NS5a inhibitor,
and our own nucleotide, PSI-938. This advances one of our key goals at Pharmasset:
to develop our nucleotide analogs as the backbone of interferon-free HCV
therapy.”  

Related Articles Read More >

Astellas
Astellas to spend $70M on new biotech campus in South San Francisco
Rainin
Mettler Toledo Rainin expands facilities in Vacaville, California
Elemental Machines
Elemental Machines aims to enlist lab freezers in fight against climate change 
Pfizer logo
Pfizer seeks to comply with voluntary Net-Zero Standard by 2040

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards